Skip to main content
Clinical Trials/NCT00387803
NCT00387803
Completed
Phase 2

VENTAK CHF/CONTAK CD Biventricular Pacing Study

Boston Scientific Corporation1 site in 1 country581 target enrollmentStarted: February 1998Last updated:

Overview

Phase
Phase 2
Status
Completed
Enrollment
581
Locations
1
Primary Endpoint
Composite of all-cause mortality, heart failure hospitalization, and ventricular tachyarrhythmia

Overview

Brief Summary

The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.

Detailed Description

Patients enrolled received a device with cardiac resynchronization therapy (CRT) and defibrillation. Patients were randomized to CRT on or off for up to six months and evaluated for mortality, hospitalization, and functional outcomes including exercise capacity, quality of life, symptomatic status, and echocardiographic analysis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Symptomatic heart failure
  • Left ventricular ejection fraction \<= 35%
  • QRS width \>= 120 ms
  • Indicated for an implantable cardioverter defibrillator

Exclusion Criteria

  • Indicated for a pacemaker
  • Atrial tachyarrhythmias

Outcomes

Primary Outcomes

Composite of all-cause mortality, heart failure hospitalization, and ventricular tachyarrhythmia

Secondary Outcomes

  • Peak VO2
  • NYHA Class
  • Six minute walk distance
  • Quality of life
  • Echocardiographic measures

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials